Mimicking the Kidney: A Key Role in Organ-on-Chip Development
Pharmaceutical drug screening and research into diseases call for significant improvement in the effectiveness of current in vitro models. Better models would reduce the likelihood of costly failures at later drug development stages, while limiting or possibly even avoiding the use of animal models....
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-07-01
|
Series: | Micromachines |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-666X/7/7/126 |
id |
doaj-11c79740d0634407b9d5906a8af0301b |
---|---|
record_format |
Article |
spelling |
doaj-11c79740d0634407b9d5906a8af0301b2020-11-24T23:46:54ZengMDPI AGMicromachines2072-666X2016-07-017712610.3390/mi7070126mi7070126Mimicking the Kidney: A Key Role in Organ-on-Chip DevelopmentRoberto Paoli0Josep Samitier1Nanobioengineering Laboratory, Institute for Bioengineering of Catalonia (IBEC), Barcelona 08028, SpainNanobioengineering Laboratory, Institute for Bioengineering of Catalonia (IBEC), Barcelona 08028, SpainPharmaceutical drug screening and research into diseases call for significant improvement in the effectiveness of current in vitro models. Better models would reduce the likelihood of costly failures at later drug development stages, while limiting or possibly even avoiding the use of animal models. In this regard, promising advances have recently been made by the so-called “organ-on-chip” (OOC) technology. By combining cell culture with microfluidics, biomedical researchers have started to develop microengineered models of the functional units of human organs. With the capacity to mimic physiological microenvironments and vascular perfusion, OOC devices allow the reproduction of tissue- and organ-level functions. When considering drug testing, nephrotoxicity is a major cause of attrition during pre-clinical, clinical, and post-approval stages. Renal toxicity accounts for 19% of total dropouts during phase III drug evaluation—more than half the drugs abandoned because of safety concerns. Mimicking the functional unit of the kidney, namely the nephron, is therefore a crucial objective. Here we provide an extensive review of the studies focused on the development of a nephron-on-chip device.http://www.mdpi.com/2072-666X/7/7/126organ-on-chipkidneynephron-on-chipdisease modeldrug discovery |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Roberto Paoli Josep Samitier |
spellingShingle |
Roberto Paoli Josep Samitier Mimicking the Kidney: A Key Role in Organ-on-Chip Development Micromachines organ-on-chip kidney nephron-on-chip disease model drug discovery |
author_facet |
Roberto Paoli Josep Samitier |
author_sort |
Roberto Paoli |
title |
Mimicking the Kidney: A Key Role in Organ-on-Chip Development |
title_short |
Mimicking the Kidney: A Key Role in Organ-on-Chip Development |
title_full |
Mimicking the Kidney: A Key Role in Organ-on-Chip Development |
title_fullStr |
Mimicking the Kidney: A Key Role in Organ-on-Chip Development |
title_full_unstemmed |
Mimicking the Kidney: A Key Role in Organ-on-Chip Development |
title_sort |
mimicking the kidney: a key role in organ-on-chip development |
publisher |
MDPI AG |
series |
Micromachines |
issn |
2072-666X |
publishDate |
2016-07-01 |
description |
Pharmaceutical drug screening and research into diseases call for significant improvement in the effectiveness of current in vitro models. Better models would reduce the likelihood of costly failures at later drug development stages, while limiting or possibly even avoiding the use of animal models. In this regard, promising advances have recently been made by the so-called “organ-on-chip” (OOC) technology. By combining cell culture with microfluidics, biomedical researchers have started to develop microengineered models of the functional units of human organs. With the capacity to mimic physiological microenvironments and vascular perfusion, OOC devices allow the reproduction of tissue- and organ-level functions. When considering drug testing, nephrotoxicity is a major cause of attrition during pre-clinical, clinical, and post-approval stages. Renal toxicity accounts for 19% of total dropouts during phase III drug evaluation—more than half the drugs abandoned because of safety concerns. Mimicking the functional unit of the kidney, namely the nephron, is therefore a crucial objective. Here we provide an extensive review of the studies focused on the development of a nephron-on-chip device. |
topic |
organ-on-chip kidney nephron-on-chip disease model drug discovery |
url |
http://www.mdpi.com/2072-666X/7/7/126 |
work_keys_str_mv |
AT robertopaoli mimickingthekidneyakeyroleinorganonchipdevelopment AT josepsamitier mimickingthekidneyakeyroleinorganonchipdevelopment |
_version_ |
1725491746443362304 |